DRG Epidemiology’s coverage of diabetic retinopathy (DR) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of DR for each country, as well as annualized case counts projected to the national population.

All patient populations are forecast over a period of 10 years for the major mature pharmaceutical markets and other countries covered in this report. In addition to forecasting incident and prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy in the major mature pharmaceutical markets.

DRG Epidemiology’s DR forecast will answer the following questions:

  • Of all people diagnosed with DR,  how many in each of the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of DR over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

DRG Epidemiology forecasts following DR patient populations:

  • Total prevalent cases.
  • Total prevalent cases by DR severity.
  • Total prevalent cases by diagnosis scheme.
  • Diagnosed prevalent cases by drug-treatment scheme.

Note: Coverage may vary by country.

Table of contents

  • Diabetic Retinopathy - Epidemiology - Emerging Markets
    • Introduction
      • Key Findings
      • Prevalence of Diabetic Retinopathy per 1,000 People Aged 20+ in 2019 and 2029
      • Relative Sizes of the Factors Contributing to the Trend in Prevalent Cases of Diabetic Retinopathy over the Next Ten Years
      • Analysis of the Prevalent Cases of Diabetic Retinopathy in 2019 by Severity
    • Epidemiology Data
    • Methods
      • Total Prevalent Cases
      • Total Prevalent Cases by Severity
      • Diagnosed Prevalent Cases
      • Drug-Treated Prevalent Cases
    • Reference Materials
      • Literature Review
        • Studies Included in the Analysis of Diabetic Retinopathy
        • Studies Excluded from the Analysis of Diabetic Retinopathy
      • Risk/Protective Factors
        • Risk/Protective Factors for Diabetic Retinopathy
      • Bibliography

Author(s): Deepti Sharma, MPH; Abey John, MPH

Deepti started working with Decision Resources Group as an intern in early 2017 and currently works as an associate epidemiologist.She works with a team of global epidemiologists in providing robust forecast estimates for multiple indications.

Deepti holds a Master’s in Public Health degree from PGIMER School of Public Health, and a bachelor’s degree in dental surgery from HP Government Dental College from Himachal Pradesh University, India.

 

Abey John is a medical graduate with a Master’s in Public Health and has been associated with DRG since September 2015. He works with a global team of epidemiologists in performing systematic reviews of assigned diseases and prepare forecast models for clients. He also is involved in producing analyses for pharmaceutical drug developers on the descriptive epidemiology of major drug indications in mature and developing markets and have an overall experience of three years working in different healthcare sectors across the country.

Prior to joining DRG, Abey had been working with Jhpiego (an affiliate of Johns Hopkins Medical University) in implementing Family Planning Health Programs in India with collaborating with the Government of India. He also has worked with a grassroots level NGO as a health team manager which worked for the benefit of the rural population living in the foothills of the Himalayas.


Related Reports

Diabetic Macular Edema / Diabetic Retinopathy - Landscape & Forecast - Disease Landscape & Forecast

Patients with proliferative diabetic retinopathy (PDR) experience retinal damage that can eventually lead to debilitating vision deficits and...

View Details

Diabetic Macular Edema | Diabetic Retinopathy | Disease Landscape and Forecast | G7 | 2020

Patients with proliferative diabetic retinopathy (PDR) experience retinal damage that can eventually lead to debilitating vision deficits and blindness, especially with the development of diabetic...

View Details

Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Epidemiology - Janssen Proprietary Content

In this report, comissioned by Janssen in October, 2020, we estimate the following mantle cell lymphoma (MCL) patient populations for the years 2020-2030: Diagn...

View Details

Diabetic Macular Edema/Diabetic Retinopathy | Disease Landscape and Forecast | G7 | 2020

The DR / DME therapy market will grow moderately over the forecast period (6.6% annual growth through 2029); this growth will be due largely to: The launch of five new therapeuti...

View Details